Skip to main content
Lyra Therapeutics, Inc. logo

Lyra Therapeutics, Inc. — Investor Relations & Filings

Ticker · LYRA ISIN · US55234L1052 US Manufacturing
Open in API
Filings indexed 356 across all filing types
Latest filing 2023-02-02 Director's Dealing
Country US United States of America
Listing US LYRA

About Lyra Therapeutics, Inc.

https://lyratherapeutics.com/

Lyra Therapeutics, Inc. is a clinical-stage biotechnology company that develops and commercializes innovative therapies for the localized treatment of chronic rhinosinusitis (CRS). The company's product candidates are long-acting, anti-inflammatory sinonasal implants designed to deliver medication directly to sinonasal tissues. This approach aims to provide a new, long-lasting treatment option for patients with this debilitating inflammatory disease, targeting tissues that are not easily accessible with conventional therapeutic methods.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2023-02-02 English
FORM 4 SUBMISSION
Director's Dealing
2023-02-02 English
FORM 4 SUBMISSION
Director's Dealing
2023-02-02 English
8-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement, specifically the Sixth Amendment to a lease agreement. There are no financial statements or detailed financial data presented, nor is this an annual or quarterly report. The document is not a report publication announcement since it contains substantive information about the lease amendment. The nature of the filing is an update on a material contract, which fits best under Regulatory Filings (RNS) as it does not fall into other more specific categories like capital updates or management changes.
2022-11-16 English
10-Q
Interim / Quarterly Report Q3 2022
2022-11-08 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically states that the company announced its financial results for the quarter ended September 30, 2022, and that the full press release is furnished as an exhibit. The document itself does not contain detailed financial statements or substantive financial data but rather references the press release. The length is 3614 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, such a document is best classified as a Regulatory Filing (RNS) because it is a current report announcing financial results but does not contain the full financial report or detailed data itself.
2022-11-08 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.